1. Home
  2. BXSL vs IBRX Comparison

BXSL vs IBRX Comparison

Compare BXSL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

HOLD

Current Price

$24.41

Market Cap

5.6B

Sector

Finance

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$9.20

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXSL
IBRX
Founded
2018
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.1B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
BXSL
IBRX
Price
$24.41
$9.20
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$27.86
$12.60
AVG Volume (30 Days)
2.7M
31.5M
Earning Date
05-28-2026
05-18-2026
Dividend Yield
12.66%
N/A
EPS Growth
N/A
38.71
EPS
2.46
N/A
Revenue
N/A
$113,288,000.00
Revenue This Year
$2.05
$93.25
Revenue Next Year
N/A
$149.39
P/E Ratio
$9.93
N/A
Revenue Growth
N/A
668.31
52 Week Low
$23.30
$1.83
52 Week High
$33.73
$12.43

Technical Indicators

Market Signals
Indicator
BXSL
IBRX
Relative Strength Index (RSI) 45.38 59.03
Support Level N/A $2.23
Resistance Level $27.04 $12.43
Average True Range (ATR) 0.66 1.32
MACD 0.07 0.02
Stochastic Oscillator 46.37 50.38

Price Performance

Historical Comparison
BXSL
IBRX

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: